Although alterations in tau protein are not considered the earliest event in AD pathogenesis, reduction in its expression levels may be safe and beneficial to prevent or treat AD (Rapoport et al., 2002; Roberson et al., 2007; Ittner et al., 2010; Vossel et al., 2010). The gene discussed is MAPT; the disease is Alzheimer disease.